Atara resubmits tab-cel BLA to FDA for EBV+ PTLD; cash ~$22M, runway into Q1 2026

Atara Biotherapeutics, Inc.

Atara resubmitted BLA to FDA for tabelecleucel (tab-cel) for EBV+ PTLD after CRL related to manufacturing observations.
Pivotal ALLELE study showed 48.8% ORR (p<0.0001); no FDA-approved therapies in this setting.
Cash, cash equivalents and short-term investments ~$22M as of June 30, 2025; cost cuts extend runway into Q1 2026.
$40M milestone payment from Pierre Fabre due upon FDA approval; plus double-digit tiered royalties on net sales.
Transitioning tab-cel clinical studies to Pierre Fabre; Atara maintains BLA sponsorship.

item 2.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.